Patricia McMonagle

Statistics

Publications

Citations

638

H-Index

Active since

2007

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

WuXi AppTec (China)

United States Military Academy

Pfizer (United States)

Patricia McMonagle is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in molecular virology, antiviral therapy, and virology.

Publications per year

2007–2024

Publications

Susceptibilities of Genotype 1a, 1b, and 3 Hepatitis C Virus Variants to the NS5A Inhibitor Elbasvir

Rong Liu, Stephanie Curry, Patricia McMonagle et al. · Antimicrobial Agents and Chemotherapy · 2015 · 77 citations · Full text

Life Sciences, Infectious Diseases, Pharmacology +17

The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons

Frederick Lahser, Karin Bystol, Stephanie Curry et al. · Antimicrobial Agents and Chemotherapy · 2016 · 58 citations · Full text

Medicine, Infectious Diseases, Pharmacology +17

Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3

Marcelo Silva, Michelle Treitel, Donald J. Graham et al. · Journal of Hepatology · 2013 · 56 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13

I. Novel HCV NS5B polymerase inhibitors: Discovery of indole 2-carboxylic acids with C3-heterocycles

G. Anilkumar, Charles A. Lesburg, Oleg Selyutin et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 49 citations

Life Sciences, Medicinal Chemistry, Pharmacology +14

Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms

Ling Tong, Wensheng Yu, Lei Chen et al. · Journal of Medicinal Chemistry · 2016 · 47 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

1–5 of 21